With 60.1 million shares changed hands, the volume of the stock remained heavier than its average volume of 0.17 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $2.87 whereas the lowest price it dropped to was $1.96. The 52-week range on GRI shows that it touched its highest point at $30.43 and its lowest point at $1.10 during that stretch. It currently has a 1-year price target of $10.00. Beta for the stock currently stands at -1.59.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of GRI was up-trending over the past week, with a rise of 36.67%, but this was up by 62.06% over a month. Three-month performance surged to 55.30% while six-month performance fell -65.55%. The stock lost -85.44% in the past year, while it has lost -76.79% so far this year. A look at the trailing 12-month EPS for GRI yields -25.87 with Next year EPS estimates of -0.78. EPS is expected to grow by 80.04% annually over the next five years; however, over the past five years, the company experienced an annual growth rate of 70.23%.
Float and Shares Shorts:
At present, 2.52 million GRI shares are outstanding with a float of 2.51 million shares on hand for trading. On 2025-08-29, short shares totaled 50513.0, which was 200.99999999999997 higher than short shares on 1753920000. In addition to Dr. W. Marc Hertz Ph.D. as the firm’s Co-Founder, CEO, President & Director, Dr. Vipin Kumar Chaturvedi Ph.D. serves as its Co-Founder & Chief Scientific Officer.
An Overview of Recent Financials:
Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on 2025-06-30, GRI reported revenue of $0.0 and operating income of -$2897000.0. The EBITDA in the recently reported quarter was -$2896000.0 and diluted EPS was -$1.31.
Analysts Ratings:
In the same way, a target price assigned to a stock can also reveal much about its potential. With GRI analysts setting a high price target of 34.0 and a low target of 10.0, the average target price over the next 12 months is 22.0. Based on these targets, GRI could surge 1558.54% to reach the target high and rise by 387.8% to reach the target low. Reaching the average price target will result in a growth of 973.17% from current levels.
EPS: Estimates vs Actual
It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy. Analysts have provided yearly estimates in a range of -$48.11 being high and -$48.11 being low. For GRI, this leads to a yearly average estimate of -$48.11. The surprise factor in the prior quarter was -$3.79. Based on analyst estimates, the high estimate for the next quarter is -$0.22 and the low estimate is -$1. The average estimate for the next quarter is thus -$0.61.
